NCT07611890 Dexmedetomidine vs Lignocaine for Reducing Intubation-Induced Hemodynamic Responses in Cardiac Surgery: A Randomized Controlled Trial
| NCT ID | NCT07611890 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Rawalpindi Institute of Cardiology |
| Condition | Laryngoscopic Stress Response |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2026-05-21 |
| Primary Completion | 2026-08-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 70 participants in total. It began in 2026-05-21 with a primary completion date of 2026-08-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
After confirming eligibility, written informed consent will be obtained by a trained team member who is not involved in assigning treatment or giving the study medication. Each participant will receive a unique study number to protect privacy. Participants will be randomly assigned to receive one of the study medications using a chance-based method.The study medication will be administered through a vein before placement of the breathing tube. Blood pressure and pulse rate will be measured before the procedure and at several time points after the breathing tube is inserted.
Eligibility Criteria
Inclusion Criteria: American Society of Anesthesiologists (ASA) physical status III-IV. Patients who are at risk of cardiovascular events Exclusion Criteria: 1. Patients with known hypersensitivity to dexmedetomidine and Lignocaine. 2. Patients on medications that could interfere with the study (e.g., beta-blockers, calcium channel blockers). 3. Pregnant or lactating women. 4. Patients with a history of airway anomalies or difficult intubation.
Contact & Investigator
Qudsia Anjum, MBBS,FCPS
STUDY CHAIR
Rawalpindi Institute of Cardiology
Frequently Asked Questions
Who can join the NCT07611890 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Laryngoscopic Stress Response. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07611890 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07611890 currently recruiting?
Yes, NCT07611890 is actively recruiting participants. Contact the research team at zujajnamrah20@gmail.com for enrollment information.
Where is the NCT07611890 trial being conducted?
This trial is being conducted at Rawalpindi, Pakistan.
Who is sponsoring the NCT07611890 clinical trial?
NCT07611890 is sponsored by Rawalpindi Institute of Cardiology. The principal investigator is Qudsia Anjum, MBBS,FCPS at Rawalpindi Institute of Cardiology. The trial plans to enroll 70 participants.